At a Glance
Lombard Medical Technologies (LMT) is the holding company of a medical devices group that aims to become a leading developer of innovative solutions for the treatment of vascular and other diseases.
In particular LMT is:
| • | producing the next generation of vascular devices addressing the unmet needs of the aortic aneurysm market; and |
| • | targeting potential market opportunities valued at over $1 billion. |
The Group has two main divisions:
| • | the Cardiovascular Devices Division developing and commercialising innovative devices to treat vascular conditions such as Abdominal Aortic Aneurysms (AAA); and |
| • | the Polymer Coatings Division which develops programmable, multi-drug delivery coatings for coronary stents as well as coatings for other medical devices such as catheters. |
Marketed Products | |
 | |
| Aorfix™ | A second-generation bifurcated stent graft, CE Mark approved in the EU for the treatment of Abdominal Aortic Aneurysms (AAA). |
| |
| EndoRefix™ | A patented endovascular stapling device that has CE Mark approval for the fixation of endovascular stent grafts. FDA approval for this indication is expected later this [2008] year following the completion of a small clinical trial. |
| |
Lead Development Products | |
| |
| Aorfix™ (US) | IDE approval has been received from the FDA and pivotal trials of the AAA began 2006, PMA filing with the FDA is expected in 2009. |
| |
| Thoracic stent graft | A stent graft for the treatment of Thoracic Aortic Aneurysms (TAA). |
| |
| |
| |
| |
Distributors | |
| |
| Distributors | Aorfix™ is currently marketed by distributors in 16 countries. (Click on distributors for a full list and contact details) |
| |
Technologies | |
| |
| PEP™ | This programmable drug elution profile (PEP™) coating can adjust the timing and amount of one or two drugs released by a drug eluting stent over one month or more. |
Updated March 2008 | |
| |